P108 for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
P108 may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed P108 in detail.
, Oral administration of Korean perilla frutescens leaf extract shows potential therapeutic effects against COVID-19 in a SH101 hamster model, Frontiers in Virology, doi:10.3389/fviro.2025.1685444
Background and objectives The outbreak of the COVID-19 pandemic has made the development of effective treatments a critical global issue. This study investigated whether Korean perilla ( Perilla frutescens var. frutescens ) leaf ethanol extract (P108) showed therapeutic potential against COVID-19 using the SH101 Roborovski hamster model. Materials and methods The COVID-19 infection model was established by intranasal administration of SARS-CoV-2 suspension into SH101 Roborovski hamsters. Experimental groups received P108 at dosages of 1,000 and 3,000 mg/kg/day, with additional groups for normal control (no treatment), vehicle control (0 mg/kg/day with vehicle only), and positive control (Paxlovid at 20 mg/kg/day). All substances were administered orally via gavage using a sonde. Treatment effects were assessed by monitoring changes in body temperature, clinical signs, body weight, levels of D-dimer and fibrin degradation products, interleukin concentrations, viral titers, immune cell counts, and lung pathology. Statistical significance was determined for differences with a p-value ≤ 0.05. Results Hamsters infected with SARS-CoV-2 exhibited typical COVID-19 disease progression, including marked hypoactivity by 4 days post-inoculation (dpi). Both P108- and Paxlovid-treated groups initially developed fever but subsequently recovered, with body weight restoration comparable to the normal control group. At 5 dpi, high-dose P108 and Paxlovid treatment resulted in reduced viral loads in lung tissues. Notably, high-dose P108 demonstrated cytokine modulation and viral load reduction trends similar to those observed with Paxlovid, as detailed in the Results and Figure Legends. P108 treatment significantly lowered fibrin degradation product levels, IL-6, and TNF-α while increasing IL-10. Histological analysis showed reduced pulmonary inflammation in the P108-treated groups. Conclusion The results of this study suggest that P108 may inhibit SARS-CoV-2 replication and reduce systemic inflammatory responses. These findings support the continued development of P108 as a candidate for preventive or early-intervention strategies against COVID-19. However, its efficacy following delayed treatment initiation (e.g., after symptom onset) has not yet been demonstrated and warrants further investigation.